325 related articles for article (PubMed ID: 16368879)
1. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
2. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
[TBL] [Abstract][Full Text] [Related]
3. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
4. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
[TBL] [Abstract][Full Text] [Related]
5. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
[TBL] [Abstract][Full Text] [Related]
6. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
7. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.
Draghi M; Pashine A; Sanjanwala B; Gendzekhadze K; Cantoni C; Cosman D; Moretta A; Valiante NM; Parham P
J Immunol; 2007 Mar; 178(5):2688-98. PubMed ID: 17312110
[TBL] [Abstract][Full Text] [Related]
8. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
Jamieson AM; Diefenbach A; McMahon CW; Xiong N; Carlyle JR; Raulet DH
Immunity; 2002 Jul; 17(1):19-29. PubMed ID: 12150888
[TBL] [Abstract][Full Text] [Related]
9. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
10. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction.
Adam C; King S; Allgeier T; Braumüller H; Lüking C; Mysliwietz J; Kriegeskorte A; Busch DH; Röcken M; Mocikat R
Blood; 2005 Jul; 106(1):338-44. PubMed ID: 15769894
[TBL] [Abstract][Full Text] [Related]
11. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
[TBL] [Abstract][Full Text] [Related]
12. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
13. NKG2D stimulation of CD8
Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
[TBL] [Abstract][Full Text] [Related]
14. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
15. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
16. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.
Liu K; Idoyaga J; Charalambous A; Fujii S; Bonito A; Mordoh J; Wainstok R; Bai XF; Liu Y; Steinman RM
J Exp Med; 2005 Dec; 202(11):1507-16. PubMed ID: 16330814
[TBL] [Abstract][Full Text] [Related]
17. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
18. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction.
Kim KD; Choi SC; Kim A; Choe YK; Choe IS; Lim JS
Int Immunopharmacol; 2001 Nov; 1(12):2117-29. PubMed ID: 11710541
[TBL] [Abstract][Full Text] [Related]
20. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
